Expires March 10, 2023
This "Continual Improvement" webinar will cover how the COVID-19 pandemic has presented a variety of challenges, but has also been an incredible learning opportunity. Learn about the ups, downs, twists, and turns that have been part of the clinical laboratory COVID-19 safety rollercoaster ride. Lessons learned, challenges and best practices, and resources available on clinical laboratory safety will be discussed.
Patricia (Pat) Hlavka, CSP
Quality Management Services
Department of Laboratory Medicine and Pathology
Mayo Clinic, Rochester, Minnesota
Upon completion of this activity, participants should be able to:
This series is appropriate for laboratory administrators and managers, quality assurance and control staff, supervisors, and other laboratory personnel who are dedicated to continuous quality and process improvement.
Mayo Clinic Laboratories is approved as a provider of continuing education programs in the Clinical Laboratory Sciences by the ASCLS P.A.C.E.® program. This program has been approved for a maximum of 1.0 P.A.C.E.® contact hour.
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for Clinical Laboratory Sciences for the State of California. This program has been approved for 1.0 contact hour.
Mayo Clinic Laboratories is approved as a Continuing Education Accrediting Agency for the Clinical Laboratory Sciences for the State of Florida. Florida Board of Clinical Laboratory Personnel has designated this program for Supervision/Administration, Quality Control/Quality Assurance credit. This program has been approved for 1.0 contact hour.
Level of instruction for this program is intermediate.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: firstname.lastname@example.org